16 November 2023
Even in places where it win approval, the high cost of Casgevy is likely to limit who can benefit from it.
“The challenge is that these therapies will be very expensive so a way of making these more accessible globally is key,” said Davies.
The treatment’s price has not yet been settled in the United Kingdom, but estimates suggest that it could cost roughly US$2 million per patient, in line with the pricing of other gene therapies.
“We have not established a list price for the UK at this time and are focused on working with the health authorities to secure reimbursement and access for eligible patients as quickly as possible,” a Vertex spokesperson told Nature.
-
Tags
#United Kingdom